Table 1.

Clinical trials for the treatment of ACLF.

Drug/Therapy	Target	Phase	Trial number
HepaStem	Inhibits HSC activation, reduce collagen secretion and downregulation of pro-inflammatory environment.	II	NCT04229901
HepaStem	Mentioned above	II	NCT02946554
Umbilical cord derived MSCs	Improves liver fibrosis and regeneration	II	NCT04822922
Allogenic ABCB5-positive MSCs	Suppress inflammation and improve wound healing	I/II	NCT03860155
Combination of Simvastatin plus Rifaximin	Simvastatin reduce HSC activation and proliferation, increase liver sinusoidal function and decrease inflammation, Rifaximin prevent hepatic encephalopathy	IIIII	NCT03780673
Ribavirin	Hepatitis E virus infection	II	NCT01698723
PEG3350	Hepatic encephalopathy	IV	NCT03987893
Branched Chain Amino Acids	Hepatic encephalopathy	I	NCT04238416
Thymosin-α1	Treats immune suppression	N/A	NCT03082885
RL-1 Novel Human-derived bio artificial liver treatment	Improves hepatic function	N/A	NCT04195282
Albumin Plus Midodrine vs. Albumin	Reduces incidence of paracentesis induced circulatory dysfunctions	N/A	NCT04474262
Glucocorticoids	Inhibits inflammation	N/A	NCT01344174

HSC, Hepatic stellate cells; MSCs, Mesenchymal stem cells; N/A, Not applicable.